Clinical Trial Update: Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years [Phase 1]

View source ↗

Summary

Phase 1 safety and dose-ranging study of acellular pertussis vaccine and an acellular pertussis-tetanus-diphtheria booster vaccine in healthy adults aged 18-40;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Acellular Pertussis-Tetanus-Diphtheria Booster Vaccine (tetanus toxoids, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap))
• Acellular pertussis vaccine (acellular pertussis vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Pertussis, Whooping Cough | Phase 1 | Status: COMPLETED | Results posted: 2014-09-18